Dennie Meijer

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/6366680/publications.pdf

Version: 2024-02-01

17	133	1477746 6	1281420 11
papers	citations	h-index	g-index

19	19	19	96
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	External Validation and Addition of Prostate-specific Membrane Antigen Positron Emission Tomography to the Most Frequently Used Nomograms for the Prediction of Pelvic Lymph-node Metastases: an International Multicenter Study. European Urology, 2021, 80, 234-242.	0.9	35
2	Targeting PSMA Revolutionizes the Role of Nuclear Medicine in Diagnosis and Treatment of Prostate Cancer. Cancers, 2022, 14, 1169.	1.7	15
3	Biochemical Persistence of Prostate-specific Antigen after Robot-assisted Laparoscopic Radical Prostatectomy: Tumor localizations using PSMA PET/CT imaging. Journal of Nuclear Medicine, 2021, 62, jnumed.120.252528.	2.8	11
4	The Predictive Value of Preoperative Negative Prostate Specific Membrane Antigen Positron Emission Tomography Imaging for Lymph Node Metastatic Prostate Cancer. Journal of Urology, 2021, 205, 1655-1662.	0.2	10
5	Predicting early outcomes in patients with intermediateâ€•and highâ€•risk prostate cancer using prostateâ€•specific membrane antigen positron emission tomography and magnetic resonance imaging. BJU International, 2022, 129, 54-62.	1.3	10
6	Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography Is Associated with Improved Oncological Outcome in Men Treated with Salvage Radiation Therapy for Biochemically Recurrent Prostate Cancer. European Urology Oncology, 2022, 5, 146-152.	2.6	9
7	Management impact of 18F-DCFPyL PET/CT in hormone-sensitive prostate cancer patients with biochemical recurrence after definitive treatment: a multicenter retrospective study. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 2960-2969.	3.3	8
8	Standardised uptake values as determined on prostateâ€•specific membrane antigen positron emission tomography/computed tomography is associated with oncological outcomes in patients with prostate cancer. BJU International, 2022, 129, 768-776.	1.3	7
9	Prostate Cancer Development Is Not Affected by Statin Use in Patients with Elevated PSA Levels. Cancers, 2019, 11, 953.	1.7	6
10	Nuclear Imaging for Bone Metastases in Prostate Cancer: The Emergence of Modern Techniques Using Novel Radiotracers. Diagnostics, 2021, 11, 117.	1.3	6
11	Clinical verification of 18F-DCFPyL PET-detected lesions in patients with biochemically recurrent prostate cancer. PLoS ONE, 2020, 15, e0239414.	1.1	6
12	Prostate Specific Membrane Antigen Positron Emission Tomography/Computerized Tomography in the Evaluation of Initial Response in Candidates Who Underwent Salvage Radiation Therapy after Radical Prostatectomy for Prostate Cancer. Journal of Urology, 2021, 205, 1100-1109.	0.2	4
13	18F-DCFPyL Uptake in an Incidentally Detected Follicular Lymphoma by PET/CT Performed for Biochemically Recurrent Prostate Cancer. Clinical Nuclear Medicine, 2020, 45, e96-e97.	0.7	2
14	SUVs Are Adequate Measures of Lesional ¹⁸F-DCFPyL Uptake in Patients with Low Prostate Cancer Disease Burden. Journal of Nuclear Medicine, 2021, 62, 1264-1269.	2.8	2
15	External Validation of Two Nomograms Developed for 68Ga-PSMA-11 Applied to the Prostate-specific Membrane Antigen Tracer 18F-DCFPyl: Is Prediction of the Optimal Timing of Salvage Therapy Feasible?. European Urology Open Science, 2021, 28, 47-51.	0.2	2
16	Reply by Authors. Journal of Urology, 2021, 205, 1108-1109.	0.2	0
17	Reply by Authors. Journal of Urology, 2021, 205, 1662-1662.	0.2	0